Investor Presentation

**1. Financial Highlights:** IOLCP's Q1 FY26 financial results show Revenue from Operations reached ₹551.7 Cr (+9.8% YoY) and Profit After Tax (PAT) hit ₹34.0 Cr (+14.4% YoY). The company reported an EBITDA margin of 12.4%, PAT margin of 6.1%, and a healthy 0.07 Debt to Equity Ratio. **2. Strategic Initiatives & Growth Drivers:** A key strategic shift involves expanding the non-Ibuprofen pharma portfolio, now contributing 34% of segment revenue.

A new ₹5.5 Cr Minoxidil facility (120 MTPA) is planned by Dec 2025. IOLCP acquired 101 acres for future expansion and aims to boost export revenue to ~40% through regulatory filings.

Backward integration enhances cost efficiency. **3. Business Developments:** IOLCP obtained REACH registration for Acetic Anhydride, enabling EU exports, and earned an EcoVadis Silver Medal for strong sustainability performance. **4. Market Position & Competitive Advantage:** Global leader in Ibuprofen (~30% market share) with unique full backward integration.

Also a top producer of Iso Butyl Benzene.

Extensive regulatory filings (16 DMFs, 19 CEPs) and a robust R&D pipeline reinforce its strong market position. **5. Investor Implications:** These updates suggest positive growth potential from product diversification, capacity expansion, and improved global market access.

Investors should monitor project execution.